Category Archives: Parkinson’s Treatment

Dr Marvin's WHY this works so well! "I have seen more miracles in the first 3 months that I used this technology than in 50 years of traditional medicine." Norman Marvin, MD Pro 7 Leader, LifeVantage Dr. David Perlmutter's research on Parkinson treatment with Glutathione http://www.youtube.com Learn more about Protandim's natural science product featured on ABC Primetime News: renewmygenes.com Lifevantage is a publicly traded corporation based in Utah, USA with stock symbol LFVN.From:wealthycopyViews:380 3ratingsTime:01:05:39More inEntertainment Continued here: Dr Marvin's WHY this works so well! - Video … Continue reading →

Public release date: 24-Oct-2012 [ | E-mail | Share ] Contact: David Cameron david_cameron@hms.harvard.edu 617-432-0441 Harvard Medical School Scientists may have discovered why the standard treatment for Parkinson's disease is often effective for only a limited period of time. Their research could lead to a better understanding of many brain disorders, from drug addiction to depression, that share certain signaling molecules involved in modulating brain activity. A team led by Bernardo Sabatini, Takeda Professor of Neurobiology at Harvard Medical School, used mouse models to study dopamine neurons in the striatum, a region of the brain involved in both movement and learning. In people, these neurons release dopamine, a neurotransmitter that allows us to walk, speak and even type on a keyboard. When those cells die, as they do in Parkinson's patients, so does the ability to easily initiate movement. Current Parkinson's drugs are precursors of dopamine that are then converted into dopamine by cells in the brain. The flip side of dopamine dearth is dopamine hyperactivity. Heroin, cocaine and amphetamines rev up or mimic dopamine neurons, ultimately reinforcing the learned reward of drug-taking. Other conditions such as obsessive-compulsive disorder, Tourette syndrome and even schizophrenia may also be related to the … Continue reading →

ESPOO, FINLAND--(Marketwire - Oct 24, 2012) - ODM-101, a new levodopa product currently developed by Orion for the treatment of Parkinson's disease, has successfully completed Phase II Proof of Concept trial. The key results indicate that ODM-101 was more efficacious than the reference product Stalevo in the treatment of advanced Parkinson's disease patients. The study included more than 100 patients in Europe. Professor Claudia Trenkwalder, the Principal Investigator of the ODM-101 Proof of Concept study, comments: "This phase II study demonstrated that ODM-101 has potential to be significantly more effective than Stalevo in the daily treatment of Parkinson's disease patients with response fluctuations. ODM-101 reduced time periods during the day when patients do not have adequate treatment response. These benefits were possible without an increase in troublesome involuntary movements (dyskinesia)." Stalevo, a product of Orion's own pharmaceutical R&D, has been established by long-term clinical practice as a standard medication for advanced Parkinson's patients experiencing so-called end-of-dose wearing-off symptoms associated with levodopa therapy. Stalevo is an enhanced levodopa treatment containing three active substances in one tablet: levodopa and the enzyme inhibitors entacapone and carbidopa. Measured in overall sales of entacapone products in 2011, Orion is the world's leading manufacturer of Parkinson's … Continue reading →

Public release date: 24-Oct-2012 [ | E-mail | Share ] Contact: Marla Paul marla-paul@northwestern.edu 312-503-8928 Northwestern University CHICAGO --- In an early-stage breakthrough, a team of Northwestern University scientists has developed a new family of compounds that could slow the progression of Parkinson's disease. Parkinson's, the second most common neurodegenerative disease, is caused by the death of dopamine neurons, resulting in tremors, rigidity and difficulty moving. Current treatments target the symptoms but do not slow the progression of the disease. The new compounds were developed by Richard B. Silverman, the John Evans Professor of Chemistry at the Weinberg College of Arts and Sciences and inventor of the molecule that became the well-known drug Lyrica, and D. James Surmeier, chair of physiology at Northwestern University Feinberg School of Medicine. Their research was published Oct. 23 in the journal Nature Communications. The compounds work by slamming the door on an unwelcome and destructive guest -- calcium. The compounds target and shut a relatively rare membrane protein that allows calcium to flood into dopamine neurons. Surmeier's previously published research showed that calcium entry through this protein stresses dopamine neurons, potentially leading to premature aging and death. He also identified the precise protein involved … Continue reading →

By Rick Nauert PhD Senior News Editor Reviewed by John M. Grohol, Psy.D. on October 26, 2012 Researchers at Harvard Medical School may have solved the mystery of why the standard treatment for Parkinsons disease is often effective for only a limited period of time. Experts say their findings could lead to a better understanding of many brain disorders, from drug addiction to depression. Investigators used mouse models to study dopamine neurons in the striatum, a region of the brain involved in both movement and learning. In people, these neurons release dopamine, a neurotransmitter that allows us to perform tasks such as walking, speaking and even typing on a keyboard. When a person has Parkinsons the dopamine cells die and the ability to easily initiate movement is lost. Current Parkinsons drugs are precursors of dopamine that are then converted into dopamine by cells in the brain. On the other hand, dopamine hyperactivity is associated with drug-seeking behaviors as heroin, cocaine and amphetamines rev up or mimic dopamine neurons, ultimately reinforcing the learned reward of drug-taking. Conditions such as obsessive-compulsive disorder, Tourette syndrome and even schizophrenia may also be related to the misregulation of dopamine. In a current issue of Nature, … Continue reading →

North American Seminars, Inc. a national provider of physical therapy continuing education courses introduces Functional Techniques for the Evaluation and Treatment of Parkinson's Disease. Franklin, TN (PRWEB) October 26, 2012 This two-day intermediate level pt continuing education course provides an in-depth look at the evaluation and treatment of patients with Parkinson's disease. The most current evidence-based and advanced concepts in rehabilitation for the effective management of Parkinson's disease will be thoroughly discussed. This course enables the clinician to identify impairments and functional limitations of patients with Parkinson's disease and then implement an effective treatment plan to achieve optimal outcomes. An overview of common medications, surgical procedures and the effects they can have on rehabilitation are discussed in an interactive format. The scientific and clinical rationale for assessment and treatment strategies are thoroughly discussed in this physical therapy continuing education course. The interactive laboratory sessions throughout day two will enhance the information learned on integrative and functional treatment techniques. The techniques can be immediately applied to the clinical setting to promote positive treatment outcomes. The case studies presented enable the clinician to perform effective evaluations and to develop appropriate rehabilitation programs. Proper documentation and goal-writing guidelines are also discussed. The clinician … Continue reading →

CAMBRIDGE, Mass., Oct.17, 2012 /PRNewswire/ --NeuroPhage Pharmaceuticals, Inc. announced today positive data with NPT001 in an alpha-synuclein pre-clinical model for Parkinson's disease (PD). The study was funded by The Michael J. Fox Foundation (MJFF). NPT001 is a first-in-class drug candidate with potential disease-modifying activity that disrupts and clears a variety of amyloid aggregates in the brain. In addition to reducing beta amyloid and tau aggregates in Alzheimer's disease (AD) preclinical studies, the new study demonstrates that NPT001 disrupts alpha-synuclein fibrils which are thought to play a critical role in PD. The study was conducted in collaboration with Dr. Eliezer Masliah at the University of California San Diego (UCSD) and demonstrated that a single NPT001 treatment produced significant reductions in neuropathology along with improved motor performance in the PD model. Specifically, NPT001 significantly reduced alpha-synuclein deposits in the brain and restored dopamine-producing cells to normal function. Deficits in dopamine production are responsible for many of the behavioral dysfunctions in PD. In addition, NPT001 was well-tolerated and produced no observable adverse effects. The data will be presented at the upcoming 2013 ADPD meeting in Florence, Italy. "The effects produced by NPT001 are robust and impressive, and the treatment improved the critical functions … Continue reading →

Public release date: 16-Oct-2012 [ | E-mail | Share ] Contact: Connie Hughes Connie.Hughes@wolterskluwer.com 646-674-6348 Wolters Kluwer Health Philadelphia, Pa. (October 16, 2012) Electrical stimulation using extradural electrodesplaced underneath the skull but not implanted in the brainis a safe approach with meaningful benefits for patients with Parkinson's disease, reports the October issue of Neurosurgery, official journal of the Congress of Neurological Surgeons. The journal is published by Lippincott Williams & Wilkins, a part ofWolters Kluwer Health. The technique, called extradural motor cortex stimulation (EMCS), may provide a less-invasive alternative to electrical deep brain stimulation (DBS) for some patients with the movement disorder Parkinson's disease. The study was led by Dr. Beatrice Cioni of Catholic University, Rome. Study Shows Safety and Effectiveness of Extradural Brain Stimulation The researchers evaluated EMCS in nine patients with Parkinson's disease. Over the past decade, DBS using electrodes implanted in specific areas within the brain has become an accepted treatment for Parkinson's disease. In the EMCS technique, a relatively simple surgical procedure is performed to place a strip of four electrodes in an "extradural" locationon top of the tough membrane (dura) lining the brain. The electrodes were placed over a brain area called the motor cortex, … Continue reading →

Newswise BIRMINGHAM, Ala. For decades, patients with Parkinsons disease (PD) have had the same experience. Their hands start to shake uncontrollably, their limbs become rigid and they lose their balance. Years before those movement problems set in, many begin struggling with fainting, incontinence, sexual dysfunction, anxiety and depression. Many patients are still treated with a 42-year-old drug called L-DOPA, which temporarily staves off symptoms but can itself cause heart arrhythmias, stomach bleeding and hallucinations. This punishing experience may explain in part why patients with PD die at twice the rate of those without the disease in the years after their diagnosis. In this light, its best to tread carefully when talking about early study results that promise something better. That said, a team of researchers at the University of Alabama at Birmingham is excited. The UAB team has identified a set of experimental drugs called LRRK2 inhibitors that may go beyond symptom relief to directly counter the inflammation and nerve cell death at the root of Parkinsons. At least, these effects have been suggested in mouse and cell culture studies meant to approximate human disease. UAB researchers reported on these findings today in a presentation at Neuroscience 2012, the annual … Continue reading →

PRINCETON, N.J.--(BUSINESS WIRE)-- As part of GE Healthcares ongoing commitment to provide resources for those living with movement disorders, the company announced today a new online patient and caregiver resource http://www.Move2Answers.com. The website brings together tools and activities from national and community organizations to educate visitors about Parkinsons disease (PD) and parkinsonian syndromes (PS), the importance of early diagnosis and the benefits of movement (e.g., exercise, dance, stretching) in developing new skills that can help make everyday tasks easier. I believe that people with movement disorders like PD deserve a team approach as they strive to maintain their quality of life," said David Leventhal, Program Manager and founding teacher of the Dance for PD program, a collaboration between Mark Morris Dance Group and Brooklyn Parkinson Group. "When diagnosticians, somatic instructors, scientists, physicians, therapists, dance artists, caregivers and people with movement disorders pool resources, ideas and complementary approaches, the path to living better with movement disorders becomes clearer, and the range of positive options available to each individual expands." Move2Answers.com offers visitors informative tools that help patients and caregivers understand more about their disease, prepare for a visit with their healthcare team, find local support groups and learn about the benefits … Continue reading →